Amazon Technologies - mmWave Radar Oxygen and Vital Signs Monitoring Patent
Summary
The USPTO granted Amazon Technologies Patent US12599307B1 for a method of concurrent monitoring of indoor oxygen concentration levels and human vital signs using mmWave radar sensors. The technology employs triangular and ramp-type chirp signals to detect vital signs such as heart rate and respiratory rate, while RSSI measurements at approximately 60 GHz determine oxygen concentration in the ambient environment. The patent includes 20 claims.
What changed
The USPTO granted Amazon Technologies a patent for a method using mmWave radar sensors to concurrently monitor oxygen concentration levels and human vital signs. The technology employs a triangular-type chirp signal and a ramp-type chirp signal to generate data indicative of vital signs such as heart rate and respiratory rate, while measuring RSSI values at approximately 60 GHz to determine oxygen concentration in an ambient environment.
This patent grant affects technology companies and healthcare monitoring system developers who may wish to design or implement similar non-contact vital signs and environmental monitoring solutions. Amazon now holds exclusive rights to this technology, which could impact future product development in smart home devices, healthcare monitoring systems, and workplace safety applications.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Concurrent monitoring of indoor oxygen concentration levels and human vital signs with mmWave radar sensors
Grant US12599307B1 Kind: B1 Apr 14, 2026
Assignee
Amazon Technologies, Inc.
Inventors
Cyril Arokiaraj Arool Emmanuel
Abstract
Technologies directed to are monitoring human vital signs with mmWave radars are described. One method sends a first signal having a first chirp that is a triangular-type chirp that increases in frequency for a first period and decreases in frequency for a second period and a second chirp that is a ramp-type chirp that increases in frequency for a third period. The method receives a second signal corresponding to the first signal. The method generates, using the first chirp and a first portion of the second signal, a third signal indicative of a human vital sign, such as a heart rate or a respiratory rate. The method measures a received signal strength indicator (RSSI) value of a second portion of the second signal at approximately 60 GHz. The method determines, using the RSSI value, a value indicative of oxygen-concentration in an ambient environment of the monitoring device.
CPC Classifications
A61B 5/0205 A61B 2560/0242 G01S 7/2923 G01S 13/282 G01S 13/88 H04B 17/318
Filing Date
2024-10-14
Application No.
18914644
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Diagnosis & Surgery (A61B)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Diagnosis & Surgery (A61B) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.